At a glance
Lilly announced a limited physician-led expanded-access pathway for some adults with refractory obesity and serious complications who cannot enter a relevant clinical trial. It is not a broad public launch, an ordinary prescription, or a retail pharmacy program.
Update — August 16, 2026
On August 12, Eli Lilly filed six federal lawsuits against U.S. companies selling black-market retatrutide. This makes the expanded-access program even more important as the legitimate physician-led path. For patients evaluating online sellers, we published a companion piece: Authentic vs. Counterfeit Retatrutide — A Patient Safety Guide →
What Lilly announced on August 3, 2026
On August 3, Eli Lilly said it would allow a limited number of patients to receive early access to investigational retatrutide before U.S. FDA approval. The company said it had built an expanded-access program and was actively reviewing requests from health care providers. Reuters’ report characterized the program as a limited pre-approval route, not a general availability announcement.
There is now a public registry record: NCT07629401, Pre-approval Expanded Access of Retatrutide. The record is listed as available and identifies Lilly as sponsor. It confirms that the program is individual-patient expanded access, rather than a conventional interventional study with treatment sites and enrollment slots.
What “expanded access” means in FDA terms
Expanded access, often called compassionate use, is a possible pathway for a person with a serious or immediately life-threatening disease or condition to receive an investigational medical product outside a clinical trial when no comparable or satisfactory alternative is available. The FDA also expects that trial enrollment is not possible, the potential benefit justifies the risks, and access will not interfere with development of the product. FDA’s expanded-access overview stresses that investigational products have not been found safe and effective for the requested use and can have unexpected serious side effects.
In practical terms, this is a treatment-use exception with oversight—not a shortcut through the normal approval process. The manufacturer has to agree to supply the medicine, a treating clinician has to support and manage the request, and regulatory and institutional-review requirements can apply. It also does not make the medicine commercially approved or generally prescribable.
Who the program targets
The registry record is more specific than the initial announcement. All public inclusion criteria are listed below; they are requirements to be considered, not a guarantee of approval:
- Age: 18 years or older.
- Refractory obesity: BMI of at least 35 kg/m² despite adherence to and tolerance of the highest available dose of chronic weight-management therapy.
- Serious complications: at least two serious or life-threatening obesity-related complications for which the person is currently receiving standard of care.
- No practical trial option: inability to participate in an ongoing trial of retatrutide or a similar investigational medicine because of eligibility criteria or lack of a reasonably accessible enrolling site.
- Shared decision-making: all standard treatment options, including bariatric surgery, must have been discussed with the patient.
- Safety: no medical contraindication to retatrutide therapy.
These requirements make the intended population much narrower than “people interested in a new weight-loss medicine.” They focus on people with severe, difficult-to-treat obesity plus high clinical need after ordinary options have been assessed. They should not be generalized to everyone with obesity, and they do not establish that retatrutide is safe or effective for any individual patient.
How this differs from clinical trial enrollment
A clinical trial is research. It has a fixed protocol, defined inclusion and exclusion criteria, scheduled study visits, data collection, and often a placebo or comparator group. For example, TRIUMPH-3 was a completed randomized study of retatrutide and placebo in people with obesity and established cardiovascular disease. Its registry record shows why trial participation is not simply a medication request.
Expanded access is different: the immediate purpose is treatment for an individual who cannot participate in a suitable trial. It does not promise randomization, and it is not a way to bypass serious safety or medical suitability questions. Lilly’s general policy says the company encourages trial participation when possible and considers individual-patient requests through the treating physician when expanded access may be the only option. Lilly’s policy page describes that process and the threshold conditions it applies to investigational medicines generally.
What is known about the request path—and what is not
What is public: the request is physician-led. Lilly’s general expanded-access policy directs a treating physician who believes access may be the only option to make a formal request with required medical information. In the United States, Lilly lists 1-800-Lilly-Rx (1-800-545-5979) for physicians and says it generally responds within five business days after receiving the information. That policy is general, so it should not be read as a separate retatrutide guarantee; the retatrutide registry itself names “Physician Inquiries for Lilly Clinical Trial Information” as contact rather than publishing a patient application form.
What remains unknown publicly as of August 8: how many patients Lilly will accept; whether and how long any individual request will be approved; the drug supply and dosing details; costs to patients; insurance coverage; site or monitoring arrangements; required documentation beyond the stated criteria; and actual decision timelines for retatrutide cases. There is no public direct-to-patient application, public clinic-location list, or announced price. Reuters likewise reported the limited program and provider-request review, rather than a retail enrollment process.
How it fits the Q1 2027 filing timeline
Expanded access does not mean an FDA approval has occurred or is imminent. Lilly has said it plans to submit a U.S. biologics license application for retatrutide in Q1 2027. Reuters’ July 23 filing report confirms the company plan; an FDA review decision date has not been announced. Lilly’s general policy says expanded-access programs are phased out once a medicine receives commercial approval, which is another reason this should be viewed as a limited bridge rather than a product launch.
Alternative legitimate path right now: find a trial
For people who do not meet the expanded-access criteria, the appropriate current route to explore is a legitimate clinical trial. Search ClinicalTrials.gov for retatrutide studies, read the study record carefully, and discuss suitability with a clinician. Recruiting status, distance to a site, criteria, placebo assignment, visits, and potential risks all matter. A closed or completed study is not an access route; TRIUMPH-3, for instance, is completed.
Compounded retatrutide and “research” sellers are not expanded access
Do not confuse the new program with products marketed online as “compounded,” “research use,” or similar language. Expanded access concerns authentic investigational medicine supplied through the manufacturer under a physician-led and regulated pathway. It is not an authorization for a consumer to buy a product online, self-dose, or treat an unapproved product as pharmacy-equivalent. Retatrutide remains investigational, and product quality, identity, dosing, and safety claims outside an authorized pathway should not be assumed.
For the evidence that made Lilly’s filing plan possible, read our TRIUMPH-3 results explainer. For the unresolved heart-outcomes question, see our cardiovascular outcomes guide. Patients should work with a licensed treating clinician rather than relying on online sellers or promotional claims.